R Fantozzi
Overview
Explore the profile of R Fantozzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
683
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Signoriello E, Foschi M, Lanzillo R, Frau J, Cocco E, Borriello G, et al.
J Neurol
. 2024 Apr;
271(7):4039-4045.
PMID: 38568225
Introduction: Cladribine is an oral immune reconstitution therapy for relapsing multiple sclerosis (RMS). Hormonal and immune changes are responsible for the decline of disease activity in the third trimester of...
2.
Martinelli V, Albanese M, Altieri M, Annovazzi P, Arabi S, Bucello S, et al.
Eur Rev Med Pharmacol Sci
. 2022 Feb;
26(3):935-946.
PMID: 35179760
Objective: Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating, disimmune disease of the central nervous system whose etiology and pathogenesis remain poorly understood, due to its complex and multifactorial nature....
3.
Ferraro D, Annovazzi P, Lanzillo R, Calabrese M, Fantozzi R, De Luca G, et al.
J Neurol Sci
. 2021 Apr;
424:117430.
PMID: 33838554
The prevalence of trigeminal neuralgia (TN) in patients with Multiple Sclerosis (MS) is higher than in the general population and its management can be particularly challenging due to a number...
4.
Tortorella C, Solaro C, Annovazzi P, Boffa L, Buscarinu M, Buttari F, et al.
Neurol Sci
. 2020 Apr;
41(8):2249-2253.
PMID: 32240416
In the last years, change in multiple sclerosis (MS) therapeutic scenario has highlighted the need for an improved doctor-patient communication in advance of treatment initiation in order to allow patient's...
5.
Chesi P, Marini M, Mancardi G, Patti F, Alivernini L, Bisecco A, et al.
Neurol Sci
. 2020 Mar;
41(8):2231-2240.
PMID: 32198654
Objective: Aim of the research was to define the quality of life of Italian neurologists and nurses' professional caring for multiple sclerosis, to understand their living the clinical practice and...
6.
Ferese R, Scorzolini L, Campopiano R, Albano V, Griguoli A, Giardina E, et al.
Acta Virol
. 2017 Sep;
61(3):273-279.
PMID: 28854791
In the last few years, polymerase chain reaction analysis is frequently required to improve the detection of pathogen infections in central nervous system as a potential cause of neurological disorders...
7.
Collino M, Benetti E, Rogazzo M, Chiazza F, Mastrocola R, Nigro D, et al.
Br J Pharmacol
. 2014 Aug;
171(24):5802-15.
PMID: 25164531
Background And Purpose: The haematopoietic activity of erythropoietin (EPO) is mediated by the classic EPO receptor (EpoR) homodimer, whereas tissue-protective effects are mediated by a heterocomplex between EpoR and the...
8.
Totaro R, Lugaresi A, Bellantonio P, Danni M, Costantino G, Gasperini C, et al.
Int J Immunopathol Pharmacol
. 2014 Jul;
27(2):147-54.
PMID: 25004826
We evaluated efficacy of natalizumab in relapsing-remitting multiple sclerosis patients in a clinical practice setting. We report data on the first consecutive 343 patients receiving natalizumab in 12 multiple sclerosis...
9.
Rosa A, Fantozzi R
Br J Pharmacol
. 2013 Jun;
170(1):38-45.
PMID: 23734637
The term 'neurogenic inflammation' has been adopted to describe the local release of inflammatory mediators, such as substance P and calcitonin gene-related peptide, from neurons. Once released, these neuropeptides induce...
10.
Minelli R, Occhipinti S, Gigliotti C, Barrera G, Gasco P, Conti L, et al.
Br J Pharmacol
. 2013 May;
170(2):233-44.
PMID: 23713413
Background And Purpose: Solid lipid nanoparticles containing cholesteryl butyrate (cholbut SLN) can be a delivery system for the anti-cancer drug butyrate. These nanoparticles inhibit adhesion of polymorphonuclear and tumour cells...